Joseph Edward Haigh

Dr. Joseph Edward Haigh

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
JHJoseph Edward Haigh
Joseph Edward Haigh
SRSamuel Rack
Samuel Rack
RYRuiyang Yan
Ruiyang Yan
SBSherin Babu
Sherin Babu
ODOlly Donnelly
Olly Donnelly
RMRobert Metcalf
Robert Metcalf
Cutaneous squamous cell carcinoma (cSCC) is a common cancer with increasing incidence and 5% of patients develop incurable disease, often resistant to chemotherapy. The anti-PD-1 therapy cemiplimab has shown high efficacy in clinical trials. This retrospective study evaluated the real-world effectiveness of cemiplimab in incurable cSCC and examined factors influencing response and toxicity. Data from 86 patients across three UK healthcare providers were analysed. Median progression-free survival (PFS) and overall survival (OS) were not reached, with 38% showing durable responses beyond 12 months. The overall response rate was 60.8% (95% CI 49–71), and the clinical benefit rate was 74.3% (95% CI 63–83). A head and neck primary site was associated with improved PFS (p = 0.008) and OS (p = 0.023), while concurrent immunosuppression was associated with worse PFS (p < 0.001). These findings align with clinical trials, suggesting cemiplimab is effective and safe in the recurrent/metastatic setting.

4 March 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
JHJoseph Edward Haigh
Joseph Edward Haigh
SRSamuel Rack
Samuel Rack
RYRuiyang Yan
Ruiyang Yan
SBSherin Babu
Sherin Babu
ODOlly Donnelly
Olly Donnelly
RMRobert Metcalf
Robert Metcalf
Cutaneous squamous cell carcinoma (cSCC) is a common cancer with increasing incidence and 5% of patients develop incurable disease, often resistant to chemotherapy. The anti-PD-1 therapy cemiplimab has shown high efficacy in clinical trials. This retrospective study evaluated the real-world effectiveness of cemiplimab in incurable cSCC and examined factors influencing response and toxicity. Data from 86 patients across three UK healthcare providers were analysed. Median progression-free survival (PFS) and overall survival (OS) were not reached, with 38% showing durable responses beyond 12 months. The overall response rate was 60.8% (95% CI 49-71), and the clinical benefit rate was 74.3% (95% CI 63-83). A head and neck primary site was associated with improved PFS (p=0.008) and OS (p=0.023), while concurrent immunosuppression was associated with worse PFS (p<0.001). These findings align with clinical trials, suggesting cemiplimab is effective and safe in the recurrent/metastatic setting.

5 August 2025 in Oral Oncology
Verified
Journal Article
Open access
JHJoseph Edward Haigh
Joseph Edward Haigh
KPKaran Patel
Karan Patel
LSLucy Shepherd
Lucy Shepherd
EHEmily Heathcote
Emily Heathcote
SRSamuel Rack
Samuel Rack
RMRobert Metcalf
Robert Metcalf
An evaluation of quality of life (QoL) is increasingly required for approval and reimbursement of new drug therapies. To support the evaluation of the impact of new drug therapies on QoL in single-arm studies in adenoid cystic carcinoma (ACC), we sought to determine the QoL baseline in a cohort of patients with ACC during routine follow up visits and to assess for associations with clinical or prognostic factors. An internationally-validated QoL questionnaire (EQ-5D-5L) was completed by patients with ACC referred to an experimental medicine centre. EQ-5D value scores (EQV) were calculated from each questionnaire using the EuroQol England value set. A Cox proportional hazards model was built with EQV as a time-dependent variable. Non-linear mixed effects modelling (NLME) was used to test the relationship between EQV and predictors (time, NOTCH1 status, age at diagnosis, sex, local and/or metastatic recurrence, and primary site of disease). Between 2019 and 2023, 563 questionnaires were completed by 161 patients with ACC. Median EQV was 0.81 (range -0.22 to 1.0) and mean EQV was 0.79. A decrease in EQV from 1 to 0 was associated with an eightfold increase in risk of death in the total population (HR = 0.118, 95 % CI 0.057 to 0.244, p=<0.001). No predictor had a significant impact on EQV in NLME except time (p=<0.001). For patients with ACC, a worse QoL as measured by EQ-5D-5L was associated with a significantly increased risk of death. It remains unclear if poorer QoL has a causal relationship with mortality.

21 September 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
JHJoseph Edward Haigh
Joseph Edward Haigh
KPKaran Patel
Karan Patel
SRSamuel Rack
Samuel Rack
PJPablo Jimenez-Labaig
Pablo Jimenez-Labaig
GBGuy nicholas john Betts
Guy nicholas john Betts
RMRobert Metcalf
Robert Metcalf
Salivary gland cancers (SGC) are rare tumours with limited availability of systemic therapies. Some SGC subtypes overexpress HER2, and this represents a potential therapeutic target, but the evidence base is limited. This study sought to analyse real-world data on the efficacy of HER2-directed therapies in SGC. This is a retrospective observational study using anonymised data from commercial compassionate-use access registrations and a privately funded pharmacy prescribing register. Treatment duration was defined as the time from drug initiation to treatment discontinuation. Kaplan–Meier analysis of treatment duration was performed using R for Windows (v4.3.2). A case report is also provided of an exceptional responder. Eighteen patients were identified who received HER2-directed therapies for HER2-positive recurrent/metastatic SGC, and complete data on treatment duration was available for 15/18. Histology was salivary duct carcinoma in 13/18 patients, adenocarcinoma NOS in 4/18, and carcinoma ex pleomorphic adenoma in 1/18. The median treatment duration was 8.3 months (95% CI: 6.41-not reached), and the range was 1.0–47.0 months. Choice of HER2-directed therapy varied, with ado-trastuzumab emtasine being the most common (9/18). At the time of analysis, HER2-directed therapy was ongoing for 9/15, discontinued due to disease progression for 4/15, discontinued due to toxicity for 1/15, and 1/15 was discontinued for an unspecified reason. An exceptional responder experienced a complete response with a treatment duration of 47.0 months. These real-world data are comparable to the median PFS observed with HER2-directed therapies in phase II trials and support the use of HER2-directed therapies in this group.

4 September 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
JHJoseph Edward Haigh
Joseph Edward Haigh
KPKaran Patel
Karan Patel
SRSamuel Rack
Samuel Rack
PJPablo Jimenez-Labaig
Pablo Jimenez-Labaig
GBGuy nicholas john Betts
Guy nicholas john Betts
RMRobert Metcalf
Robert Metcalf
Salivary gland cancers (SGC) are rare tumours with limited availability of systemic therapies. Some SGC subtypes overexpress HER2 and this represents a potential therapeutic target, but the evidence base is limited. This study sought to analyse real-world data on efficacy of HER2-directed therapies in SGC. This is a retrospective observational study using anonymised data from commercial compassionate-use access registrations and a privately funded pharmacy prescribing register. Treatment duration was defined as time from drug initiation to treatment discontinuation. Kaplan-Meier analysis of treatment duration was performed using R for windows (v4.3.2). A case report is also provided of an exceptional responder. Eighteen patients were identified who received HER2-directed therapies for HER2-positive recurrent/metastatic SGC, and complete data on treatment duration was available for 15/18. Histology was salivary duct carcinoma in 13/18 patients, adenocarcinoma NOS in 4/18, and carcinoma ex pleomorphic adenoma in 1/18. Median treatment duration was 8.3 months (95% CI: 6.41-not reached) and the range was 1.0-47.0 months. Choice of HER2-directed therapy varied, with ado-trastuzumab emtasine being most common (9/18). At time of analysis, HER2-directed therapy was ongoing for 9/15, discontinued due to disease progression for 4/15, discontinued due to toxicity for 1/15, and 1/15 was discontinued for an unspecified reason. An exceptional responder experienced a complete response with a treatment duration of 47.0 months. This real-world data is comparable to the median PFS observed with HER2-directed therapies in phase II trials and supports the use of HER2-directed therapies in this group.

13 June 2026 in Cancers
Verified
Journal Article
Open access
PDF file
KPKaran Patel
Karan Patel
JHJoseph Edward Haigh
Joseph Edward Haigh
SRSamuel Rack
Samuel Rack
HMHitesh Mistry
Hitesh Mistry
EHEmily Heathcote
Emily Heathcote
RMRobert Metcalf
Robert Metcalf
Background/Objectives: Adenoid cystic carcinoma (ACC) is a heterogenous disease and defining aggressive subtypes to inform surveillance and treatment strategies remains clinically pertinent. NOTCH pathway-activated ACC is associated with worse outcomes. We describe the distribution of tumour mutational burden (TMB) and characterise its relationship with NOTCH gain-of-function (GoF) mutation and survival in locally advanced or recurrent/metastatic (LA-R/M) ACC. Methods: 124 tumours from the UK NHS (NHS group) and 139 tumours from cBioPortal; MSK metTropism (MSK group) were evaluated as independent cohorts. TMB (mut/Mb) was calculated either by F1CDx or its precursor FoundationOne NGS in the NHS group, or MSK-IMPACT NGS in the MSK group. NOTCH1/2 mutations were classed as GoF if predicted to disrupt the NRR/PEST domains. Overall survival (OS) was measured from diagnosis of unresectable LA-R/M ACC. Results: Median TMB was 1.26 mut/Mb (IQR 0–2.52) in the NHS group and 1.96 (IQR 0.87–3.46) in the MSK group. NOTCH1/2 GoF mutation was seen in 16/124 (13%) in the NHS group and 22/139 (16%) in the MSK group. Median TMB for tumours with NOTCH1/2 GoF mutation was 2.52 mut/Mb (IQR 1.82–3.84) in the NHS group and 4.38 mut/Mb (IQR 3.33–4.89) in the MSK group. For tumours with NOTCH1/2 GoF mutation, median OS reduced with TMB > median of 2.52 mut/Mb (0.7 yrs vs. 2.6 yrs, p = 0.02) in the NHS group. Conclusions: LA-R/M ACC has a low TMB profile overall. Median TMB was higher in NOTCH-activated ACC in both the NHS and MSK groups and TMB may have value in further stratifying patients with LA-R/M ACC.